https://www.selleckchem.com/pr....oducts/vazegepant-hy
We hypothesize that blocking AP-2 function and thus inhibiting CME may be a novel approach to identify new druggable targets, or to increase their residence time at the plasma membrane, thereby increasing the probability for efficient therapeutic intervention. To characterize adverse ventricular remodelling after withdrawing therapy in recovered dilated cardiomyopathy (DCM). TRED-HF was a randomized controlled trial with a follow-on single-arm cross-over phase that examined the safety and feasibility of therapy withdraw
Like
Comment
Share
